Polyphor AG bags funding for murepavadin

Polyphor has secured $3.3m from the Cystic Fibrosis Foundation as support for clinical Phase I/IIa testing of its inhaled antibiotic murepavadin.

Read more

EU COVID-19 antibody ready for clinical trials

As investments into COVID-19 therapeutics is no EU priority, development is lagging behind the US. Now, CORAT Therapeutics‘ candidate COR101 is set to enter clinical testing. 

Read more

COVID-19: Moderna reports promising interim results

After BioNTech SE reported that its COVID-19 vaccine candidate BNT162b2 was over 90% efficient in a Phase III trial, Moderna Inc announced an efficacy of 94.5%.

Read more

BioNTech reports high efficacy of COVID-19 vaccine

Interim data on BioNtech’s/Pfizer’s COVID-19 vaccine candidate BNT162b2 suggest an efficacy of more than 90% – 30% better than required by the FDA.

Read more

Protein Brewery raise €22m in Series A

Lead investor Novo Growth has led a €22m Series A investment in The Protein Brewery, a Dutch company that is to supplement the market for protein alternatives by fungal protein.

Read more

Galecto raise US$85m in Nasdaq IPO

HBM portfolio company Galecto has raised US$85m through the placement of 5.67 million new shares at a price of US$15 per share at Nasdaq.
 

Read more

BI initiates Phase II testing of COVID-19 drug

Boehringer Ingelheim announced the start of Phase II studies of its oral TRPC6 blocker code-named BI 764198 in patients hospitalised for COVID-19.

Read more

3P Bio to manufacture SpyBiotech vaccine

British SpyBiotech has outsourced GMP manufacturing of its VLP vaccine platform to Navarra-based 3P Biopharmaceuticals.

Read more